Intellectual Property Rights in the Pharmaceutical Industry: Strategies for Patent Protection, Landscaping, and Litigation Management

Intellectual Property Rights (IPR) form the legal backbone that enables pharmaceutical companies to protect innovation, recover research investment, and compete in global markets. This review examines the principal categories of intellectual property relevant to the pharmaceutical sector—patents, trademarks, copyrights, industrial designs, and trade secrets—with particular emphasis on patents as the dominant instrument of protection for drug substances, formulations, and manufacturing processes. The article discusses global patent filing systems, including the shift from a First-to-Invent to a First-to-File regime in the United States, and outlines the core operational activities of a pharmaceutical IPR function: patent searching and landscaping, infringement and freedom-to-operate (FTO) analysis, patentability assessment, drafting and prosecution, and support for Paragraph IV litigation arising from Abbreviated New Drug Application (ANDA) filings. The role of pre-grant and post-grant opposition mechanisms in maintaining patent quality, the major international patent databases used for competitive intelligence, and the diverse categories of pharmaceutical patents— compound, polymorph, process, formulation, method-of-treatment, impurity, particle-size, bioequivalence, purity, and stabilization patents are also reviewed. The article also gives insight about how AI is redefining IPR in transforming the Patent Lifecycle. The review concludes by highlighting the increasingly cross-functional nature of IPR management and the challenges that generic and innovator companies face in balancing innovation incentives with access to affordable medicines.